Drug Target Review feature: "What if drug discovery took months, not decades?"

Recent Drug Target Review article highlights GATC Health’s innovative approach to the drug industry’s greatest challenges. 

Irvine, CA — August 21, 2025 — GATC Health was recently featured in an insightful article published by Drug Target Review, titled “What if drug discovery took months, not decades?” The editorial highlights GATC Health's innovative use of artificial intelligence (AI) and multiomics to accelerate drug discovery, offering a transformative approach to making the process faster, more precise, and less reliant on traditional, slow, and high-cost methods. The coverage details how GATC’s MAT (Multiomics Advanced Technology®) platform is revolutionizing the identification and validation of therapeutic targets, as well as the design of novel compounds with a focus on human biology rather than animal models.

The article features perspectives from Dr. Rahul Gupta, President of GATC Health and former White House Director of National Drug Control Policy, and Ian Jenkins, Chief Science Officer and Co-founder. Together, they explain how their platform enables the repurposing of existing drugs, the rescue of shelved drug candidates, and the development of new therapeutics for both common and rare diseases—delivering hopeful solutions for patients and addressing long-standing inefficiencies across the industry.

This recognition underscores GATC Health’s leadership at the forefront of AI-driven biomedical innovation and reaffirms its commitment to improving global health outcomes through faster, safer, and more ethical drug development. Stakeholders are encouraged to read the full article for a detailed look at the company’s transformative mission and ongoing collaborations within healthcare, regulatory, and research communities.

Read the full article here.

About GATC Health Corp

GATC Health Corp is a technology company that is transforming drug discovery and development through its AI-driven platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (“MAT”) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and derisk drug pipelines by predicting efficacy, safety, and off-target effects. Founded in 2020, GATC Health is headquartered in Irvine, CA, and has facilities in Utah, West Virginia and Washington DC. For more information, visit gatchealth.com.